Age modifies the response to recombinant human thyrotropin

Thyroid

Volumn 20, Issue 12, 2010, Pages 1377-1384

  Over, Rebecca ^a,b   Nsouli Maktabi, Hala ^c   Burman, Kenneth D ^b   Jonklaas, Jacqueline ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b WASHINGTON HOSPITAL CENTER   (United States)

^c MEDSTAR RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CREATININE; RADIOACTIVE IODINE; RECOMBINANT THYROTROPIN; THYROTROPIN;

ADULT; AGE DISTRIBUTION; ARTICLE; BODY MASS; BODY WEIGHT; CANCER DIAGNOSIS; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DIAGNOSTIC IMAGING; FEMALE; GENDER; GLOMERULUS FILTRATION RATE; HUMAN; MALE; MENOPAUSE; PRIORITY JOURNAL; THYROID CANCER; THYROTROPIN BLOOD LEVEL; TREATMENT RESPONSE;

ADULT; AGE FACTORS; AGED; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; THYROID NEOPLASMS; THYROTROPIN;

EID: 78649690874     PISSN: 10507256     EISSN: None     Source Type: Journal    
DOI: 10.1089/thy.2010.0177     Document Type: Article

References (36)

1. Pacini F, Castagna MG 2008 Diagnostic and therapeutic use of recombinant human TSH (rhTSH) in differentiated thyroid cancer. Best Pract Res Clin Endocrinol Metab 22: 1009-1021.
2. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F 2005 rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49-64. (Pubitemid 40477087)
3. Mazzaferri EL, Massoll N 2002 Management of papillary and follicular (differentiated) thyroid cancer: new paradigms using recombinant human thyrotropin. Endocr Relat Cancer 9:227-247.
4. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, et al. 1994 Diagnostic use of recombinant human thyro-tropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78:188-196.
5. Davies TF 2000 Analysis of the results of phase III controlled clinical trials with recombinant human thyrotropin: developing a clinical guide. Endocr Pract 6:391-395.
6. Robbins RJ, Tuttle RM, Sharaf RN, Larson SM, Robbins HK, Ghossein RA, Smith A, Drucker WD 2001 Preparation by recombinant human thyrotropin or thyroid hormone withdrawal are comparable for the detection of residual differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:619-625.
7. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD 1997 Comparison of administration of recombinant human thy-rotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337:888-896.
8. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC 1999 A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Me-tab 84:3877-3885.
9. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C 2006 Radioiodine ablation of thyroid remnants after preparation with recombi-nant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91:926-932.
10. Luster M, Lassmann M, Haenscheid H, Michalowski U, Incerti C, Reiners C 2000 Use of recombinant human thy-rotropin before radioiodine therapy in patients with advanced differentiated thyroid carcinoma. J Clin Endocrinol Metab 85:3640-3645.
11. Pacini F, Molinaro E, Castagna MG, Lippi F, Ceccarelli C, Agate L, Elisei R, Pinchera A 2002 Ablation of thyroid residues with 30mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal. J Clin Endocrinol Metab 87:4063-4068.
12. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49: 764-770.
13. Pacini F, Molinaro E, Castagna MG, Agate L, Elisei R, Ceccarelli C, Lippi F, Taddei D, Grasso L, Pinchera A 2003 Recombinant human thyrotropin-stimulated serum thyro-globulin combined with neck ultrasonography has the highest sensitivity in monitoring differentiated thyroid carcinoma. J Clin Endocrinol Metab 88:3668-3673.
14. Mazzaferri EL, Robbins RJ, Spencer CA, Braverman LE, Pacini F, Wartofsky L, Haugen BR, Sherman SI, Cooper DS, Braunstein GD, Lee S, Davies TF, Arafah BM, Ladenson PW, Pinchera A 2003 A consensus report of the role of serum thyroglobulin as a monitoring method for low-risk patients with papillary thyroid carcinoma. J Clin Endocrinol Metab 88:1433-1441. (Pubitemid 36623351)
15. Pacini F, Molinaro E, Lippi F, Castagna MG, Agate L, Cec-carelli C, Taddei D, Elisei R, Capezzone M, Pinchera A 2001 Prediction of disease status by recombinant human TSH-stimulated serum Tg in the postsurgical follow-up of differentiated thyroid carcinoma. J Clin Endocrinol Metab 86:5686-5690.
16. Vitale G, Lupoli GA, Ciccarelli A, Lucariello A, Fittipaldi MR, Fonderico F, Panico A, Lupoli G 2003 Influence of body surface area on serum peak thyrotropin (TSH) levels after recombinant human TSH administration. J Clin Endocrinol Metab 88:1319-1322.
17. Castagna MG, Pinchera A, Marsili A, Giannetti M, Molinaro E, Fierabracci P, Grasso L, Pacini F, Santini F, Elisei R 2005 Influence of human body composition on serum peak thyrotropin (TSH) after recombinant human TSH administration in patients with differentiated thyroid carcinoma. J Clin Endocrinol Metab 90:4047-4050.
18. Montesano T, Durante C, Attard M, Crocetti U, Meringolo D, Bruno R, Tumino S, Rubello D, Al-Nahhas A, Colandrea M, Maranghi M, Travascio L, Ronga G, Torlontano M 2007 Age influences TSH serum levels after withdrawal of l-thyroxine or rhTSH stimulation in patients affected by differentiated thyroid cancer. Biomed Pharmacother 61:468-471.
19. Levey AS, Coresh J, Greene T, Stevens LA, Zhang YL, Hendriksen S, Kusek JW, Van Lente F 2006 Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247-254.
20. Levey A, Greene T, Kusek J 2000 A simplified equation to predict glomerular filtration rate from serum creatinine. J Am Soc Nephrol 11:A0828 (abstract).
21. Cuttelod S, Lemarchand-Beraud T, Magnenat P, Perret C, Poli S, Vannotti A 1974 Effect of age and role of kidneys and liver on thyrotropin turnover in man. Metabolism 23:101-113.
22. Constant RB, Weintraub BD 1986 Differences in the metabolic clearance of pituitary and serum thyrotropin (TSH) derived from euthyroid and hypothyroid rats: effects of chemical deglycosylation of pituitary TSH. Endocrinology 119:2720-2727.
23. Faglia G, Beck-Peccoz P, Piscitelli G, Medri G 1987 Inappropriate secretion of thyrotropin by the pituitary. Horm Res 26:79-99.
24. Thotakura NR, Desai RK, Bates LG, Cole ES, Pratt BM, Weintraub BD 1991 Biological activity and metabolic clearance of a recombinant human thyrotropin produced in Chinese hamster ovary cells. Endocrinology 128: 341-348.
25. Maxon HR 1999 Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer. Q J Nucl Med 43:313-323.
26. Maxon HR, Thomas SR, Hertzberg VS, Kereiakes JG, Chen IW, Sperling MI, Saenger EL 1983 Relation between effective radiation dose and outcome of radioiodine therapy for thyroid cancer. N Engl J Med 309:937-941.
27. Castro MR, Bergert ER, Goellner JR, Hay ID, Morris JC 2001 Immunohistochemical analysis of sodium iodide symporter expression in metastatic differentiated thyroid cancer: correlation with radioiodine uptake. J Clin Endocrinol Metab 86:5627-5632.
28. Maxon HR, Thomas SR, Boehringer A, Drilling J, Sperling MI, Sparks JC, Chen IW 1983 Low iodine diet in I-131 ablation of thyroid remnants. Clin Nucl Med 8:123-126.
29. Pluijmen MJ, Eustatia-Rutten C, Goslings BM, Stokkel MP, Arias AM, Diamant M, Romijn JA, Smit JW 2003 Effects of low-iodide diet on postsurgical radioiodide ablation therapy in patients with differentiated thyroid carcinoma. Clin En-docrinol (Oxf) 58:428-435.
30. Kogai T, Endo T, Saito T, Miyazaki A, Kawaguchi A, Onaya T 1997 Regulation by thyroid-stimulating hormone of sodium/iodide symporter gene expression and protein levels in FRTL-5 cells. Endocrinology 138:2227-2232.
31. Schlumberger M, Tubiana M, De Vathaire F, Hill C, Gardet P, Travagli JP, Fragu P, Lumbroso J, Caillou B, Parmentier C 1986 Long-term results of treatment of 283 patients with lung and bone metastases from differentiated thyroid carcinoma. J Clin Endocrinol Metab 63:960-967.
32. Tala Jury HP, Castagna MG, Fioravanti C, Cipri C, Brianzoni E, Pacini F 2010 Lack of association between urinary iodine excretion and successful thyroid ablation in thyroid cancer patients. J Clin Endocrinol Metab 95:230-237.
33. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ri-card M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654.
34. Koong SS, Reynolds JC, Movius EG, Keenan AM, Ain KB, Lakshmanan MC, Robbins J 1999 Lithium as a potential adjuvant to 131I therapy of metastatic, well differentiated thyroid carcinoma. J Clin Endocrinol Metab 84:912-916.
35. Edmonds CJ, Hayes S, Kermode JC, Thompson BD 1977 Measurement of serum TSH and thyroid hormones in the management of treatment of thyroid carcinoma with radio-iodine. Br J Radiol 50:799-807.
36. Elisei R, Schlumberger M, Driedger A, Reiners C, Kloos RT, Sherman SI, Haugen B, Corone C, Molinaro E, Grasso L, Leboulleux S, Rachinsky I, Luster M, Lassmann M, Busaidy NL, Wahl RL, Pacini F, Cho SY, Magner J, Pinchera A, Ladenson PW 2009 Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal. J Clin Endocrinol Metab 94:4171-4179.